MarginsXMarginsX
Home › Markets › Health Care › TXMD

TherapeuticsMD Inc. (TXMD)

TXMD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.81
-3.21% on the day
Market cap
$20.9M
Nano cap
Revenue · 2025
$3.0M
+71.6% on 2024
Net income · 2025
-$569K
-18.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K/A (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/25743/000121390026037918/0001213900-26-037918-index.htm. Net income: SEC 10-K/A (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTXMD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000025743
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2025

LineValue
Revenue$3.0M
Net income-$569K
Operating income-$4.4M
Net margin-18.8%
Operating margin-145.3%
Revenue growth+71.6%
Cash$7.5M
Total assets$37.7M
P/E (computed)Net income was not positive
P/S (computed)6.9×

Warning signs

Cash runway
Cash-flow positive
$9.2M cash at June 30, 2026
Share count, 1 year
0.0%
2025-11-11 to 2026-11-09 · +9.4% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$14K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements."
10-Q 2026-11-13
Cash and burn$9.2M cash; operating cash flow $774K a quarter.Report 2026-06-30
Shares outstanding11,574,362 (2026-11-09); 11,574,362 a year earlier; 10,575,240 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCarr, Riggs & Ingram LLC, Palm Beach Gardens, Florida, United States; changed auditors 1 time in 24 months8-K 4.01 2026-01-21
Late filings, 12 months1 NT noticeNT 10-K 2026-04-01
Insider trades, 12 monthsBought $14K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$869K$155K$779K$9.2MNo debt tags$3.3M10-Q 2026-08-11
Q1 2026
2026-03-31
$724K$95K$944K$8.4MNo debt tags$3.4M10-Q 2026-05-12
Q4 2025
2025-12-31
$893K-$619K$375K$7.5MNo debt tags$3.0M10-K/A 2026-04-01
Q3 2025
2025-09-30
$784K$152K$999K$7.1MNo debt tags$2.8M10-Q 2025-11-12
Q2 2025
2025-06-30
$952K$551K$381K$6.1MNo debt tags$2.6M10-Q 2026-08-11
Q1 2025
2025-03-31
$393K-$653K$699K$5.7MNo debt tags$1.8M10-Q 2026-05-12
Q4 2024
2024-12-31
$667K$252K$17K$5.1MNo debt tags$1.8M10-K/A 2026-04-01
Q3 2024
2024-09-30
$547K-$609K-$71K$5.0MNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2022-03-24
Latest annual report
ANNUAL REPORT
10-K/A2026-04-01
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-13
Latest current report
CURRENT REPORT
8-K2026-11-13
Latest proxy
PROXY STATEMENT
DEFA14A2025-11-03

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.5%
1 month-4.6%
3 months-10.1%
Year to date+14.7%
1 year+15.4%
From 52-week high-32.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CPHIChina Pharma Holdings Inc.$0.4800-7.35%$20.7M
IGCIGC Pharma Inc.$0.1750-0.57%$20.4M
SHPHShuttle Pharmaceuticals Holdings Inc.$4.24-6.40%$20.2M
CELUCelularity Inc.$0.6191-1.75%$20.1M
AYTUAytu BioPharma Inc.$1.82+1.68%$19.8M
ATOSAtossa Therapeutics Inc.$1.93-1.53%$19.3M
RNAZTransCode Therapeutics Inc.$1.35-1.46%$22.9M
COCPCocrystal Pharma Inc.$0.9777-0.24%$18.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier